OMRON is a Japanese electronics company whose healthcare arm, a global brand in home blood-pressure monitors, flies the banner of 'Going for Zero'—zero heart attacks and strokes. Since about 90% of heart attacks and strokes are said to be preventable through daily blood-pressure monitoring and behavior change, OMRON drives prevention centered on measuring at home. In 2025 a new monitor that automatically detects atrial fibrillation (AFib) with AI at every reading received FDA De Novo authorization and won Best in Class at the Digital Health Awards. With Kyoto University it develops AI for personalized blood-pressure management that predicts events from biometric data.
B
NARRATIVE VALUE
Certainty
●●● high
●●● high
ABCDEFG
There is no confirmed −; independently verified + decide the position (B). No unreachable strike-through.= non-additive meter
As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3BHistory grows each quarter
OMRON: Toward zero heart attacks and strokes, with home blood-pressure monitors. The letter is B; certainty is high. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)
Main narrative
One person’s story (N1)
+ A single story
Many strokes and heart attacks stem from unnoticed high blood pressure. With OMRON's home monitors and 'Going for Zero,' people learn their own blood pressure daily and can act to prevent. The benefit appears as a collective: about 90% of heart attacks and strokes are said to be preventable through daily monitoring and behavior change.
Source nature: OMRON Healthcare / FDA / P1 First-party / independent (FDA). Positive effects are not used to offset negatives.
Positive / negative effects
+ effects
- A monitor that automatically detects atrial fibrillation (AFib) with AI at every reading won Best in Class at the 2025 Digital Health Awards, and it develops AI for personalized blood-pressure management with Kyoto University.P1 First-party / OMRON Healthcare
− effects (confirmed)
- No confirmed −.
Watching (unconfirmed; not counted in the assessment)
- A listed, for-profit device maker
- the preventive effect depends on continued device use and behavior change (indirect)
- access depends on price.
Looking ahead (not included in the assessment)
- Verifying real outcomes (fewer events) of prevention; encouraging continued use and behavior change; reaching low- and middle-income countries; accuracy of AI prediction and user sovereignty.
A second look
The plus is prevention of major events—stroke and heart attack—through home blood-pressure measurement and AFib detection (People), backed by the '90% preventable' evidence, FDA authorization and an award. But it is a listed, for-profit device maker, and the preventive effect depends on continued device use and behavior change (indirect). Weighing the genuine, large-scale preventive-health plus, B/high.
Sources
+N1OMRON Healthcare / FDA｜AI-Powered AFib Detection (FDA De Novo)｜2025｜🔗
+ effectOMRON Healthcare｜Going for Zero / 2025 Digital Health Awards｜2025｜🔗
How to read this assessment
A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
- Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
- The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
- Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
- The letter (assessment) and certainty (how reliable the information is) are separate axes.
This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.
Terms: Narrative Value = an assessment (A–G) of the distance between the narrative an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top